In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

Recognized for Advancing Global Wound Care Through Innovation and EfficacyAMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- ...

Human wounds take almost three times as long to heal as those of other primates, which may come down to our lack of fur ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

A 5-year-old girl from Kozhikode undergoing treatment for rabies died due to the virus despite getting preventive vaccination ...

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...

Patient, 47, sprained his back while lifting heavy objects before seeking traditional Chinese medicine treatment, ...

Abeona Therapeutics' Zevaskyn, a cell therapy based on engineered keratinocytes harvested from patients, has been approved in ...

A 47-year-old man here had his left lower leg amputated after developing a severe bacterial infection days following ...